阿可替尼对比伊布替尼治疗经治慢性淋巴细胞白血病:首个随机III期试验结果
该开放标签随机非劣效III期试验纳入533例经治CLL患者,随机接受阿可替尼100mg每日两次或伊布替尼420mg每日一次。中位随访40.9个月,两组中位PFS均为38.4个月(HR 1.00,95%CI 0.79-1.27),阿可替尼非劣效于伊布替尼;
要点
- 阿可替尼在经治CLL中PFS非劣效于伊布替尼,中位PFS均为38.4个月。
- 阿可替尼组房颤/房扑发生率显著低于伊布替尼组(9.4% vs 16.0%)。
- 阿可替尼因不良事件停药率低于伊布替尼(14.7% vs 21.3%)。
核心结论
- 在经治CLL患者中,阿可替尼对比伊布替尼显示非劣效的无进展生存期,且心血管不良事件更少。
研究设计与样本
- 开放标签、随机、非劣效III期试验,纳入533例经治CLL患者,随机分配至阿可替尼100mg每日两次(n=268)或伊布替尼420mg每日一次(n=265),直至疾病进展或不可耐受毒性。
主要发现
- 中位随访40.9个月,两组中位PFS均为38.4个月(95%CI:阿可替尼33.0-38.6,伊布替尼33.0-41.6;HR 1.00,95%CI 0.79-1.27)。
- ≥3级感染发生率阿可替尼组30.8%,伊布替尼组30.0%;Richter转化发生率3.8% vs 4.9%。
- 中位总生存期两组均未达到(HR 0.82,95%CI 0.59-1.15),死亡人数阿可替尼组63例(23.5%),伊布替尼组73例(27.5%)。
- 因不良事件停药率阿可替尼组14.7%,伊布替尼组21.3%。
临床怎么用
- 对于经治CLL患者,阿可替尼可作为伊布替尼的替代选择,尤其关注心血管不良事件风险的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Among Bruton's tyrosine kinase inhibitors, acalabrutinib has greater selectivity than ibrutinib, which we hypothesized would improve continuous therapy tolerability. We conducted an open-label, randomized, noninferiority, phase III trial comparing acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia (CLL). METHODS: Patients with previously treated CLL with centrally confirmed del(17)(p13.1) or del(11)(q22.3) were randomly assigned to oral acalabrutinib 100 mg twice daily or ibrutinib 420 mg once daily until progression or unacceptable toxicity. The primary end point was independent review committee-assessed noninferiority of progression-free survival (PFS). RESULTS: Overall, 533 patients (acalabrutinib, n = 268; ibrutinib, n = 265) were randomly assigned. At the data cutoff, 124 (46.3%) acalabrutinib patients and 109 (41.1%) ibrutinib patients remained on treatment. After a median follow-up of 40.9 months, acalabrutinib was determined to be noninferior to ibrutinib with a median PFS of 38.4 months in both arms (95% CI acalabrutinib, 33.0 to 38.6 and ibrutinib, 33.0 to 41.6; hazard ratio: 1.00; 95% CI, 0.79 to 1.27). All-grade atrial fibrillation/atrial flutter incidence was significantly lower with acalabrutinib versus ibrutinib (9.4% v 16.0%; P = .02); among other selected secondary end points, grade 3 or higher infections (30.8% v 30.0%) and Richter transformations (3.8% v 4.9%) were comparable between groups and median overall survival was not reached in either arm (hazard ratio, 0.82; 95% CI, 0.59 to 1.15), with 63 (23.5%) deaths with acalabrutinib and 73 (27.5%) with ibrutinib. Treatment discontinuations because of adverse events occurred in 14.7% of acalabrutinib-treated patients and 21.3% of ibrutinib-treated patients. CONCLUSION: In this first direct comparison of less versus more selective Bruton's tyrosine kinase inhibitors in CLL, acalabrutinib demonstrated noninferior PFS with fewer cardiovascular adverse events.
引用
- Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. J Clin Oncol. 2021. PMID: 34310172. doi:10.1200/JCO.21.01210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。